CD8A and cancer: An emerging therapeutic bile acid, 4-norursodeoxycholic acid (NorUDCA), is used in primary sclerosing cholangitis (PSC) to target mTORC1 signaling to affect glycolysis and prevent CD8+ T cells from undergoing further energy damage, thus directing them back on the right path to function properly to defend against viruses and cancer cells [105].